FDA will hold Advisory Committee meeting on July 29th to review deramiocel for treatment of Duchenne

Capricor Therapeutics has shared that the US FDA will hold an Advisory Committee meeting on July 29, 2026, to discuss the company’s Biological License Application (BLA) seeking approval of deramiocel, an investigational cell therapy for the treatment of Duchenne.  It will be possible to watch this meeting via live streaming, and more details will be found  here once the meeting is added to the listing of FDA events. 

Press Release HERE